Concepedia

Author

Trinayan Kashyap

Karyopharm Therapeutics (United States)

Also Known As

T Kashyap, T. Kashyap, Trinayan Kashyap

141

Publications

1.6K

Citations

19

H-Index

29

Concepts

All Affiliations

Karyopharm Therapeutics (United States)The Ohio State UniversityWayne State UniversityMoffitt Cancer CenterDana-Farber Cancer Institute
TK

About

Trinayan Kashyap is an author at Karyopharm Therapeutics (United States) specializing in tumor biology, medicine, and cell biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

703

2

Cell Biology

8

8

703

3

Immunology

3

3

256

4

Molecular Medicine

1

1

11

5

Pathology

1

1

299

Trinayan Kashyap

×

25

Publications

1.5K

Citations

19

H-Index

YearCitations

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

Y-T Tai, Yosef Landesman, Chirag Acharya,

Leukemia

2013

299

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Ramiro Garzon, Michael R. Savona, Rachid Baz,

Blood

2017

147

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death

Trinayan Kashyap, Christian Argueta, Amro Aboukameel,

Oncotarget

2016

125

XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus

Parvathi Ranganathan, Trinayan Kashyap, Xueyan Yu,

Clinical Cancer Research

2016

93

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

Joel G. Turner, Trinayan Kashyap, Jana L. Dawson,

Oncotarget

2016

88

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis

Kellie R. Machlus, Stephen Wu, Prakrith Vijey,

Blood

2017

71

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents

Trinayan Kashyap, Christian Argueta, Thaddeus J. Unger,

Oncotarget

2018

67

Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies

Melissa A. Fischer, Sharon Friedlander, Maria P. Arrate,

Blood Advances

2020

66

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer

Sabiha Kazim, Mokenge P. Malafa, Domenico Coppola,

Molecular Cancer Therapeutics

2015

61

Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo

Trinayan Kashyap, Jackelyn Murray, Christopher J. Walker,

Antiviral Research

2021

54

Page 1